Orphazyme AS (CHIX:ORPHAC) Accounts Payable & Accrued Expense : kr11.70 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Accounts Payable & Accrued Expense?

Orphazyme AS's quarterly accounts payable & accrued expense declined from Jun. 2021 (kr99.10 Mil) to Dec. 2021 (kr87.63 Mil) and declined from Dec. 2021 (kr87.63 Mil) to Jun. 2022 (kr11.70 Mil).

Orphazyme AS's annual accounts payable & accrued expense increased from Dec. 2019 (kr50.20 Mil) to Dec. 2020 (kr129.62 Mil) but then declined from Dec. 2020 (kr129.62 Mil) to Dec. 2021 (kr87.63 Mil).

Orphazyme AS Accounts Payable & Accrued Expense Historical Data

The historical data trend for Orphazyme AS's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Accounts Payable & Accrued Expense Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

46.60

52.70

50.20

129.62

87.63

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial									59.43	129.62	99.10	87.63	11.70

Orphazyme AS Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines